CA
NZ
UK
AU
IND
US
Tenon Medical, Inc. (NASDAQ: TNON) secured a USPTO notice of allowance for a patent covering sacroiliac joint stabilization systems and methods.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) initiated a $350 million common stock offering, featuring a $52.5 million overallotment option, to support avexitide launch preparations and R&D expansion following its LUCIDITY Phase 3 success.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 21% at $0.47 after the company partnered with SDVOSB AvMEDICAL to distribute CyPath Lung across federal healthcare networks, including VA medical centers.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares closed up 64% at $35.11 after the company reported that avexitide reached its primary FDA-agreed endpoint in the Phase 3 LUCIDITY study for post-bariatric hypoglycemia (PBH).
Moderna (NASDAQ:MRNA) shares jumped roughly 94% in premarket trading, while Merck (NYSE:MRK) shares rose close to 7%.
Merck & Co. (NYSE:MRK), a global healthcare company with a pharmaceuticalBusinessanchored by its KEYTRUDA immunotherapy franchise, is trading sharply higher in pre-market activity after announcing positive topline results from the Phase 3 INTerpath-001 trial. The trial evaluated intismeran autogene, an individualized mRNA-based neoantigen therapy …
Moderna (NASDAQ:MRNA), a Cambridge, Massachusetts based biotechnology company that pioneers messenger RNA technology for vaccines and therapeutics, is trading sharply higher in pre-market activity after announcing positive topline results from the Phase 3 INTerpath-001 trial. The trial evaluated intismeran autogene, an individualized mRNA-based neoantigen …
AVITA Medical (NASDAQ:RCEL) shares are trading modestly lower in pre-market action Wednesday, down 1.96% to $9.66, pulling back after shares surged 24.68% Tuesday on positive PermeaDerm study results. The study met its primary endpoint, demonstrating a 70% economic advantage over allograft based on product …
EyePoint Pharmaceuticals (NASDAQ:EYPT) shares are trading up 5.48% in pre-market action Wednesday to $5.77, extending Tuesday's 12.32% regular-session rebound. The stock had collapsed Monday after the company reported that its pivotal Phase 3 LUGANO trial evaluating DURAVYU 2.7mg in wet age-related macular degeneration did …
INVO Fertility (NASDAQ:IVF) shares are falling further in pre-market trading Wednesday, down 8.39% to $1.31, extending Tuesday's 6.54% regular-session decline even after the company reported a return toNet Incomein its second quarter. Revenue increased 17% year-over-year to approximately $2.2 million, and the company posted …
Please wait processing your request...